Dr. Javier Cortes

Keytruda Plus Chemotherapy Improves Survival Outcome in Metastatic Triple-Negative Breast Cancer

June 20, 2020

First-line treatment with Keytruda (pembrolizumab) in combination with chemotherapy improves progression-free survival in patients with locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC), according to data presented at the 2020 ASCO Virtual Scientific Program.